Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate
Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires global rights.
Gossamer Bio made a deal to keep full control of its main medicine and plans to show it to the FDA next year. When a company owns all the rights to its best drug and has a clear plan ahead, it's a sign they believe in it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.